AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03343002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl at 10-15 min before end of surgery
Description: Label 2 syringe is filled with 1mcg/kg of fentanyl, label 1 syringe is filled with same amount of saline solution. If the surgeon notifies the anesthesiologist 10-15 minutes before the end of the operation, the syringe drug labeled 1 will be administered intravenously(that is, normal saline ). At the end of the surgery, the syringe drug labeled 2 is administered intravenously((that is, 1mcg/kg of fentanyl)
Study NCT03343002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl at end of surgery
Description: Label 2 syringe is filled with 1mcg/kg of fentanyl, label 1 syringe is filled with same amount of saline solution. If the surgeon notifies the anesthesiologist 10-15 minutes before the end of the operation, the syringe drug labeled 1 will be administered intravenously(that is, normal saline ). At the end of the surgery, the syringe drug labeled 2 is administered intravenously((that is, 1mcg/kg of fentanyl)
Study NCT03582098 — intervention group
Intervention type: DRUG
Intervention: Idelalisib
Description: Tablets were administered in accordance with the marketing authorization.
Study NCT03582098 — intervention group
Intervention type: DRUG
Intervention: Rituximab
Description: Tablets were administered in accordance with the marketing authorization.
Study NCT04328168 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ROM exercises, stretching, positioning, gait training
Study NCT04328168 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: by two physiotherapist under the supervision of a doctor
Study NCT02676232 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DARWeb
Description: Psychosocial Intervention from the cognitive-behavioral model, including different but related units for parents and children with recurrent abdominal pain.
Study NCT02112617 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Proton radiation will be delivered daily for 3-4 weeks, depending on the dose prescribed by study doctor. Treatment is delivered (Monday - Friday) for 5 days (no weekends or holidays). Each treatment the participant will lie on a table for 30-45 minutes.
Study NCT01482442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sorafenib
Description: Patients will receive continuous oral treatment with 800 mg of sorafenib daily (Nexavar, Bayer HealthCare Pharmaceuticals-Onyx Pharmaceuticals). Treatment interruptions and dose reductions (to 400 mg once daily) will be permitted for drug-related adverse effects. At the discretion of the investigator, the dose may be re-escalated to after the resolution of the adverse event.
Study NCT01482442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SIR-Sphere
Description: The first step will check patient eligibility and prepare conditioning by performing selective mesenteric and hepatic angiography (to document the arterial tumor supply and to occlude extrahepatic vessels) and 99mTc-macroaggregated albumin scintigraphy. The second step is RADIOEMBOLIZATION therapy. One to two weeks after patient eligibility and conditioning, treatment is performed with SIR-Sphere (SIRTEX Medical Ltd.,Lane Cove,Australia).
Study NCT03611920 — intervention group
Intervention type: PROCEDURE
Intervention: Tetracycline
Description: Teeth were soaked in topical tetracycline 5% for 5 minutes before replantation
Study NCT03611920 — intervention group
Intervention type: PROCEDURE
Intervention: Dexamethasone
Description: Teeth were soaked in topical dexamethasone (60μ ml-1) for 20 minutes before replantation
Study NCT00230113 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acid diet supplementation
Description: 4 gm fish oil per day
Study NCT03420872 — intervention group
Intervention type: OTHER
Intervention: Nutrient mixtures
Description: consumption of a mixture of beneficial nutrients
Study NCT02412098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eleclazine
Description: Eleclazine tablets administered orally
Study NCT05647590 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: 3 months of platinum doublet chemotherapy (cDDP / CBDCA + Pemetrexed, NVB)
Study NCT05647590 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) + Stereotactic Body Ratio Therapy (SBRT)
Description: * RT to primary tumor + SBRT to all oligometa (max. 10 intra / extracranial lesions, intracranial SD / PR)~* SBRT V \< 100 ml, if technically possible fractionation RT (40 - 50 Gy / 16 - 20 fractions), SBRT (30 Gy / 1 fraction, 50 - 60 Gy / 3 - 5 fractions) 3 - 6 weeks ... maintenance
Study NCT05647590 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy
Description: Maintenance chemotherapy will follow 3-6 weeks after RT.
Study NCT00930085 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SELDI-TOF MS for plasmatic proteic profile
Description: An extra blood sample is required to determine the plasmatic proteic profile used to identify one or several signatures which are correlated to the clinical evolution (mortality at D30).
Study NCT00295542 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambulatory blood pressure monitoring
Description: Sampling at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
Study NCT00295542 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chronotherapy, timing of antihypertensive medication
Description: Comparison of effects of awakening versus bedtime dosing
Study NCT00295542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACEI (including spirapril, enalapril, quinapril, lisinopril)
Description: Treatment at awakening versus bedtime
Study NCT00295542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARB (including valsartan, telmisartan, olmesartan)
Description: Treatment at awakening versus bedtime
Study NCT00295542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: beta blockers (including nebivolol, atenolol, carvedilol)
Description: Treatment at awakening versus bedtime
Study NCT00295542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diuretics (torasemide, indapamide, HTCZ) and doxazosin
Description: Treatment at awakening versus bedtime
Study NCT00295542 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combination therapy in essential hypertension
Description: Treatment at awakening versus bedtime
Study NCT02151669 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: Nutritional intervention conducted by a dietitian who designs a nutrition program to enhance the traditional Mediterranean diet pattern using new technology as an educational tool in primary care: DIET blog. Participants will be referred to a single annual visit and one group session per year for two years.
Study NCT02286921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone cypionate
Description: Depo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. Depo-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
Study NCT02286921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide is a white crystalline non-hygroscopic solid. It is practically insoluble in water. Enzalutamide is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides. The inactive ingredients are caprylocaproyl polyoxylglycerides, butylated hydroxyanisole, butylated hydroxytoluene, gelatin, sorbitol sorbitan solution, glycerin, purified water, titanium dioxide, and black iron oxide.
Study NCT02286921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Enanthate
Description: Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative.
Study NCT04170543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI3506
Description: Dose 1, Dose 2, Dose 3, Dose 4
Study NCT03937362 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: First clinical response evaluation (CRE-1)
Description: Consisting of: endoscopy with bite-on-bite biopsies
Study NCT03937362 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Second clinical response evaluation (CRE-2)
Description: Consisting of: PET-CT, endoscopic bite-on-bite biopsies,EUS with FNA
Study NCT05716308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A continuous nursing intervention group was established.
Description: Intervention group: Continuous nursing intervention was performed on the basis of the control group: ①A continuous nursing intervention group was established. The group members included chief physician, attending physician, head nurse, specialist nurse and nutritionist. ②The establishment of patient records, patients admitted to hospital by the primary nurse to record the basic situation of patients, including name, age, history of diabetes, DR staging, vision and blood glucose before treatment and other information. ③Personalized nursing intervention was given during hospitalization. Systematic health education was carried out for patients on admission. Targeted psychological counseling was given to some patients. ④After discharge to give continuous care, organize patients to join the WeChat group, group to share knowledge of DR-related diseases, to understand the patient 's medication, diet, vision, the patient 's questions and problems to guide and improve.
Study NCT03161652 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DME plus ranibizumab lactose pill
Description: Patients with DME with conventional intravitreal antiangiogenic therapy with ranibizumab (0.5 mg every 4 weeks for 12 weeks) will take a lactose pill (placebo) orally TID for 24 weeks. The placebo is taken on top of standard therapy for diabetes and blood pressure control.
Study NCT03161652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DME plus ranibizumab levosulpiride
Description: Patients with DME with receive intravitreal antiangiogenic therapy with ranibizumab (0.5 mg every 4 weeks for 12 weeks) will take a levosulpiride (75 mg/day) orally TID for 24 weeks. The study medication is taken on top of standard therapy for diabetes and blood pressure control.
Study NCT02016534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 337
Description: AMG 337 300mg orally daily.
Study NCT02162056 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: use of bioresorbable vascular scaffolds
Description: Implantation of bioresorbable vascular scaffolds for coronary artery disease.
Study NCT03817125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for antibiotic
Description: Placebo for antibiotic will be administered orally four times a day for 4 days, followed by a 2-3 day washout.
Study NCT03817125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin pretreatment
Description: Vancomycin (125mg) will be administered orally four times a day, followed by a 2-3 day washout.
Study NCT00230113 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: safflower oil
Description: 4 gm per day safflower oil
Study NCT00187174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: The drug is given orally in 28 day courses.
Study NCT03817125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab (480 mg) will be administered intravenously (IV) according to institutional guidelines every 4 weeks for up to 12 cycles. A cycle is defined as 4 calendar weeks.
Study NCT03817125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (480 mg) will be administered intravenously (IV) according to institutional guidelines every 4 weeks for up to 12 cycles. A cycle is defined as 4 calendar weeks.
Study NCT03817125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for SER-401
Description: Administered once a day for 7 days during the lead-in phase, followed by once a day for 8 weeks during the microbiome/anti-PD-1 treatment phase.
Study NCT03817125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER-401
Description: Administered once a day for 7 days during the lead-in phase, followed by once a day for 8 weeks during the microbiome/anti-PD-1 treatment phase.
Study NCT03879785 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screening
Description: Screening and validation of assessment tool translated into Spanish
Study NCT00927589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Intravenous repeating dose
Study NCT00927589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Intravenous repeating dose
Study NCT00927589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Intravenous repeating dose
Study NCT00596531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acamprosate
Description: Oral administration, 666 mg, tid, for 4 months
Study NCT00596531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of 2 pills, tid, for 4 months
Study NCT04823065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide Pill
Description: 4 mg Imodium, per os
Study NCT04823065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyoscine-n-butylbromide
Description: 3 X 20 mg Buscopan, intravenous
Study NCT03807570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Morus Alba L. Extract
Description: Morus Alba L. Extract 30 ml/day for 12 weeks.
Study NCT03807570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 30 ml/day for 12 weeks.
Study NCT01545648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Formulation of Dosage forms~The vial presentations of denosumab contain 60 mg/mL denosumab, 17 mM sodium acetate, and 4.7% (w/v) sorbitol, at a pH of 5.2, filled to a target deliverable volume of 1.0 mL; or 70 mg/mL denosumab, 18 mM sodium acetate and 4.6% (w/v) sorbitol, at a pH of 5.2, filled to a target deliverable volume of 1.7 mL. The prefilled syringe (PFS) drug product contains denosumab at 60 mg/mL, 17 mM sodium acetate, 4.7% (w/v) sorbitol, and 0.01% (w/v) polysorbate 20, at a pH of 5.2, filled to a target deliverable volume of 1.0 mL.~Dosage: 120 mg, monthly for total of 6 months, then every 12 weeks for 2 doses, for a total treatment course of one year~Route of administration: subcutaneous injection
Study NCT01224405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel + LH-RH analogues
Description: Docetaxel will be administered at a dose of 75 mg/m2 per square meter as a 1-hour intravenous infusion on day 1 every 21 days in association to 5 mg of prednisone orally twice daily.~In patients randomised to arms A up to 10 cycles of docetaxel will be planned in association to maintenance of LH-RH analogues administration.
Study NCT01224405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered at a dose of 75 mg/m2 per square meter as a 1-hour intravenous infusion on day 1 every 21 days in association to 5 mg of prednisone orally twice daily.~In patients randomised to arms B up to 10 cycles of docetaxel will be planned, in association to stopping LH-RH analogues.
Study NCT01224405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Patients randomised in the arms AB1 (intermittent docetaxel) will suspend treatment after at least 4 cycles if their PSA level will be reduced >50%. Docetaxel treatment will be resumed when the serum PSA will rise by >50% from the lowest PSA level recorded and will be >10 ng/mL or when there will be other evidence of disease progression. PSA progression must to be confirmed with a second assessment after 2 weeks before deciding to resume docetaxel administration.
Study NCT01224405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Docetaxel
Description: Patients randomised in the arms AB2 (continuous docetaxel) will continue treatment up to ten cycles after even if their PSA level at 4 cycles will be reduced >50% or will reach a level \<4 ng/mL.
Study NCT01224405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Docetaxel
Description: Patients randomised in the arms AB1(intermittent docetaxel) will continue treatment up to ten cycles even if their PSA level after 4 cycles will be reduced >50% or will reach a level \<4 ng/mL.
Study NCT01651117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Mentoring
Description: Patients will receive peer mentoring.
Study NCT04382729 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: The intervention group, in addition to the daily routine physical therapy, receives NMES for 15 days (5 days per week for 3 weeks). NMES is applied bilaterally using an electrical stimulator with pairs of electrodes placed transversally on the quadriceps muscles and on the gastrocnemius muscles. The stimulation protocol consists in the application of symmetrical biphasic rectangular pulses with a frequency of 30 Hz (pulse duration: 400 µs). Stimulation intensity is adjusted daily by the physical therapist to elicit a visible twitch in each muscle. The total duration of the NMES session is 30 min for the first week and 45 min for the second and third week. Stimulation (on) time is 5 s and relaxation (off) time is 15 s, thus eliciting a total of 90 evoked contractions per day during the first week and 135 contractions per day during the second and third week.
Study NCT04382729 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy Exercise
Description: The control group is subjected to a protocol of physical therapy exercises, applied once a day for 30 minutes (5 days per week for 3 weeks) by the staff physical therapists. It starts with global passive range of motion exercises, followed by active and resistive exercises (including controlled breathing exercises and respiratory muscle training), transfer to the edge of the bed or to a chair, standing and walking.
Study NCT02832232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: translational dorsal glide mobilization technique grade III
Description: Translational dorsal glide mobilization technique grade III of the atlanto-occipital joint, it is a mobilization technique of Orthopedic Manual therapy according to Kaltenborn-Evjenth concept. The aim is to produce a dorsal glide of the occipital on the atlas, which will be held back by the therapist's hand, producing a stretch component of the suboccipital muscles.~And Protocolized physiotherapeutic treatment: Three weeks of daily sessions (five a week) of stretching exercises, thermotherapy and postural education.
Study NCT02832232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pressure maintained suboccipital Inhibition technique
Description: Pressure maintained suboccipital Inhibition technique is aimed to inhibit the tone of the suboccipital muscles. Although some dorsal occipital glide is produced by the weight of the head itself, the main effect is on the muscles due to dorsally pressure is not added to the occipital.~And Protocolized physiotherapeutic treatment: Three weeks of daily sessions (five a week) of stretching exercises, thermotherapy and postural education.
Study NCT02832232 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Protocolized physiotherapeutic treatment: Three weeks of daily sessions (five a week) of stretching exercises, thermotherapy and postural education.
Study NCT02832232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Protocolized physiotherapeutic treatment: Three weeks of daily sessions (five a week) of stretching exercises, thermotherapy and postural education.
Study NCT06160609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab Mafodotin
Description: Belantamab Mafodotin will be administered.
Study NCT06160609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3174998
Description: GSK3174998 will be administered.
Study NCT02251483 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Serum-derived bovine immunoglobulin protein isolate (SBI)
Study NCT02251483 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00287586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Gel (Androgel)
Description: 7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years
Study NCT00287586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching testosterone gel daily for 3 years
Study NCT01547429 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artisan Aphakia Intraocular Lens
Description: Implantation of lens to correct refractive error in aphakic eye
Study NCT00537173 — intervention group
Intervention type: PROCEDURE
Intervention: Core Biopsy
Description: biopsy
Study NCT00537173 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Collection
Description: Blood/serum sample
Study NCT00537173 — intervention group
Intervention type: DRUG
Intervention: Paclitaxel
Description: Paclitaxel 90 mg/m2 IV, day 1, 8 and 15
Study NCT00537173 — intervention group
Intervention type: DRUG
Intervention: Avastin
Description: Avastin 10 mg/kg IV, day 1 and 15